Sensitivity analysis: overall survival treatment effect of tisagenlecleucel vs blinatumomab
| Method . | HR . | 95% CI . | P . |
|---|---|---|---|
| Unadjusted HR | |||
| Univariate Cox regression | 0.39 | 0.26-0.60 | <.001 |
| Marginal HR (adjusted) | |||
| Cox regression with sIPTW | 0.46 | 0.30-0.70 | <.001 |
| Cox regression with trimmed sIPTW | 0.46 | 0.30-0.70 | <.001 |
| Conditional HR (adjusted) | |||
| Cox regression stratified by quintiles of propensity score | 0.46 | 0.29-0.71 | <.001 |
| Cox regression adjusting for prognostic factors | 0.40 | 0.26-0.63 | <.001 |
| Cox regression adjusting for prognostic factors and propensity score | 0.39 | 0.25-0.63 | <.001 |
| Method . | HR . | 95% CI . | P . |
|---|---|---|---|
| Unadjusted HR | |||
| Univariate Cox regression | 0.39 | 0.26-0.60 | <.001 |
| Marginal HR (adjusted) | |||
| Cox regression with sIPTW | 0.46 | 0.30-0.70 | <.001 |
| Cox regression with trimmed sIPTW | 0.46 | 0.30-0.70 | <.001 |
| Conditional HR (adjusted) | |||
| Cox regression stratified by quintiles of propensity score | 0.46 | 0.29-0.71 | <.001 |
| Cox regression adjusting for prognostic factors | 0.40 | 0.26-0.63 | <.001 |
| Cox regression adjusting for prognostic factors and propensity score | 0.39 | 0.25-0.63 | <.001 |
An HR <1 indicates that tisagenlecleucel is associated with a lower hazard of death than blinatumomab after adjusting for prognostic factors.